You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.
A proteomic and targeted exome sequencing study of diffuse-type gastric cancer led to proteomic subtypes with distinct mutation, survival, and potential treatment patterns.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
Examining five types of bacterial environments in patients' stomachs, researchers found that non-Helicobacter pylori microbiota may lead to gastric cancer development.
Patients with PD-L1-expressing gastric or gastroesophageal junction tumors can now be identified for potential treatment with Keytruda using Agilent's assay.
Researchers developed a gene expression-based classifier for four gastric cancer subtypes and found that some are associated with better outcomes than others.
Shared gastric adenocarcinoma tumor features seem to span geography and ethnicity, despite shifts in the proportion of tumors from different molecular subtypes.
The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.
Eleven new recommendations were issued to address appropriate HER2 testing and clinical guidance in individuals with advanced gastroesophageal adenocarcinoma.
The company's technology will be used to analyze samples from a large cohort of Chinese volunteers to identify biomarkers for early cancer detection.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.